# A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies

> **NCT02205333** · PHASE1,PHASE2 · TERMINATED · sponsor: **MedImmune LLC** · enrollment: 48 (actual)

## Conditions studied

- Advanced Solid Tumors
- Aggressive B-cell Lymphomas

## Interventions

- **BIOLOGICAL:** MEDI6469 Monotherapy
- **BIOLOGICAL:** MEDI6469 Plus Tremelimumab
- **BIOLOGICAL:** MEDI6469 Plus Durvalumab
- **BIOLOGICAL:** MEDI6469 plus Rituximab

## Key facts

- **NCT ID:** NCT02205333
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-08-13
- **Primary completion:** 2016-04-08
- **Final completion:** 2016-04-08
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** The study was terminated early at the sponsor's discretion.
- **Last updated:** 2017-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02205333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02205333, "A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02205333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*